title: In vitro activity of novel rifamycins against gram-positive clinical isolates.
abstract: We describe novel rifamycins that have improved activity, compared with rifampin, against clinical isolates of staphylococci and streptococci, with MIC(90)s of 0.008 and 0.0005 microg/ml, respectively. This enhanced antibacterial activity, along with their potential lack of drug-drug interactions, are considerations that suggest the potential of these novel rifamycins in combination therapy to treat serious Gram-positive infections.
authors.affiliation: ActivBiotics, Inc., Lexington, MA 02421, USA. drothstein@activbiotics.com
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Murphy
authors.forename: Elena
authors.initials: E
authors.lastname: Karginova
authors.forename: Dan
authors.initials: D
authors.lastname: Sahm
authors.forename: David M
authors.initials: DM
authors.lastname: Rothstein
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004347:Drug Interactions; D013293:Enterococcus faecalis / Q000187:drug effects; D016984:Enterococcus faecium / Q000187:drug effects; D006095:Gram-Positive Cocci / Q000187:drug effects*; D008826:Microbial Sensitivity Tests; D012294:Rifamycins / Q000494:pharmacology*; D013211:Staphylococcus aureus / Q000187:drug effects; D013212:Staphylococcus epidermidis / Q000187:drug effects; D013292:Streptococcus agalactiae / Q000187:drug effects; D013296:Streptococcus pneumoniae / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D000900:Anti-Bacterial Agents; D012294:Rifamycins; D003577:Cytochrome P-450 Enzyme System